Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.

Robinson SM, Mann J, Manas DM, Mann DA, White SA.

HPB (Oxford). 2013 Aug;15(8):581-7. doi: 10.1111/hpb.12010. Epub 2012 Dec 27.

2.

Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.

Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA, Mann DA.

J Hepatol. 2013 Aug;59(2):318-26. doi: 10.1016/j.jhep.2013.04.014. Epub 2013 Apr 23.

3.

The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.

Robinson SM, Mann DA, Manas DM, Oakley F, Mann J, White SA.

Br J Cancer. 2013 Oct 29;109(9):2396-403. doi: 10.1038/bjc.2013.604. Epub 2013 Oct 10.

4.

Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.

Martinez-Balibrea E, Martínez-Cardús A, Musulén E, Ginés A, Manzano JL, Aranda E, Plasencia C, Neamati N, Abad A.

Int J Cancer. 2009 Jun 15;124(12):2905-10. doi: 10.1002/ijc.24273.

5.

mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.

Pilgrim CH, Brettingham-Moore K, Pham A, Murray W, Link E, Smith M, Usatoff V, Evans PM, Banting S, Thomson BN, Michael M, Phillips WA.

HPB (Oxford). 2011 Nov;13(11):811-6. doi: 10.1111/j.1477-2574.2011.00365.x. Epub 2011 Aug 2.

6.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

7.

Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.

Theile D, Grebhardt S, Haefeli WE, Weiss J.

Biochem Pharmacol. 2009 Dec 1;78(11):1366-73. doi: 10.1016/j.bcp.2009.07.006. Epub 2009 Jul 19.

PMID:
19622348
8.

Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.

Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, Hayashi H, Okabe H, Ootao R, Watanabe M, Takamori H, Iyama K, Baba H.

Int J Clin Oncol. 2010 Jun;15(3):263-70. doi: 10.1007/s10147-010-0046-9. Epub 2010 Mar 19.

PMID:
20238233
9.

Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.

Narita M, Oussoultzoglou E, Chenard MP, Fuchshuber P, Rather M, Rosso E, Addeo P, Jaeck D, Bachellier P.

Ann Surg Oncol. 2012 Jul;19(7):2230-7. doi: 10.1245/s10434-011-2112-6. Epub 2012 Mar 9.

PMID:
22402811
10.

Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.

Khan AZ, Morris-Stiff G, Makuuchi M.

J Hepatobiliary Pancreat Surg. 2009;16(2):137-44. doi: 10.1007/s00534-008-0016-z. Epub 2008 Dec 18. Review.

PMID:
19093069
11.

Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.

Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, Curley SA, Abdalla EK, Capussotti L, Vauthey JN.

Ann Surg Oncol. 2010 Nov;17(11):2870-6. doi: 10.1245/s10434-010-1166-1. Epub 2010 Jun 22.

PMID:
20567921
12.

Colorectal liver metastases.

Tzeng CW, Aloia TA.

J Gastrointest Surg. 2013 Jan;17(1):195-201; quiz p.201-2. doi: 10.1007/s11605-012-2022-3. Epub 2012 Oct 3. Review.

PMID:
23054896
13.

Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.

James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N, Thomas A, Greaves P, Cai H, Patel SR, Morgan B, Dennison A, Metcalfe M, Garcea G, Lloyd DM, Berry DP, Steward WP, Howells LM, Brown K.

Cancer Lett. 2015 Aug 10;364(2):135-41. doi: 10.1016/j.canlet.2015.05.005. Epub 2015 May 12.

15.

Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.

Lentz F, Tran A, Rey E, Pons G, Tréluyer JM.

Am J Pharmacogenomics. 2005;5(1):21-33. Review.

PMID:
15727486
16.

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.

Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK.

Int J Colorectal Dis. 2010 Oct;25(10):1243-9. doi: 10.1007/s00384-010-0996-4. Epub 2010 Jun 24.

17.

Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.

Rubie C, Frick VO, Ghadjar P, Wagner M, Justinger C, Graeber S, Sperling J, Kollmar O, Schilling MK.

World J Gastroenterol. 2011 Jul 14;17(26):3109-16. doi: 10.3748/wjg.v17.i26.3109.

18.

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.

Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T.

Eur J Surg Oncol. 2009 May;35(5):515-20. doi: 10.1016/j.ejso.2008.12.013. Epub 2009 Feb 5.

PMID:
19200687
19.

Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.

Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Goldwasser F, Scatton O.

Ann Surg. 2010 Mar;251(3):454-60. doi: 10.1097/SLA.0b013e3181c79403.

PMID:
20160638
20.

Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.

Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM.

Cancer. 2015 Oct 15;121(20):3649-58. doi: 10.1002/cncr.29534. Epub 2015 Jul 6.

PMID:
26149602
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk